Company intelligence / Profile preview

WELL

Jiangsu, China

Ownership: Private
Development stage: Other

Overview

Jiangsu Well Biotech is a commercial in vitro diagnostics company offering rapid point-of-care tests (POCT) and ELISA kits for pregnancy, infectious diseases including HIV and Covid‑19, drugs of abuse, tumor markers, cardiac markers, and alcohol screening, distributed globally including via an Australian subsidiary/distributor.[3][6][9][13]

Therapeutic areas: Women's HealthCardiovascularInfectious DiseasesPsychiatryOncology
Modalities: DeviceDiagnostic assayIn vitro diagnostic test
Industry: Protein Biomarker Diagnostics

Beyond the preview

Go deeper on WELL.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on WELL.

Explore the full profile